Navigation Links
First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting
Date:7/30/2008

Cruz urges more attention to diagnosis and treatment of AD among Hispanics and advises family members suspecting AD symptoms in a loved one to visit http://www.losamigosdesumemoria.com to learn more about the disease and complete an online memory screener.

The EARTH study represents Eisai and Pfizer's leadership in understanding the benefits of ARICEPT in multiple populations. The TAAAP study, published in the Journal of the National Medical Association in 2006, found that African Americans with mild to moderate AD and treated with ARICEPT experienced significant improvement in cognition and function. ARICEPT has now been studied in two underserved populations, both with higher prevalence and incidence of AD than the general population.

Alzheimer's Disease in the Hispanic Community

-- There are an estimated 200,000 Hispanics living in the U.S. with AD today, and by 2050, it is estimated that approximately 1.3 million Hispanic Americans will have the disease.

-- Due to language differences and cultural barriers, Hispanics typically wait to see a doctor until they are in a later stage of the disease -- usually three years after symptoms emerge.

-- Many Hispanics living with AD remain undiagnosed and untreated (approximately 40 percent).

-- Hispanics start showing AD symptoms nearly seven years earlier than non-Hispanics.

-- Reasons for increased AD risk in the Hispanic community include the growing senior population (age is the number one risk for disease), higher rates of diabetes and hypertension (known risk factors), and familial risk (genetics and heredity).
-- Hispanic participation in AD clinical trials remains historically low.

Information About ARICEPT Treatment in Alzheimer's Disease

ARICEPT is the only AD treatment to be approved in the U.S. for mild, moderate and severe dementia of the Alzheimer's type. While there is no c
'/>"/>

SOURCE Eisai Inc.; Pfizer Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
2. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
3. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
4. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
5. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
6. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
7. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
8. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
9. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
10. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
11. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... a $15 million milestone payment from GSK related to advancing ... with familial amyloid polyneuropathy (FAP).  "We are ... Rx , and plan to report data from the Phase ... the fifteen months of dosing and are now receiving ISIS-TTR ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... Inc. (Nasdaq: STXS ) announced today that the underwriters ... have exercised in full their over-allotment option to purchase an ... 7,475,000 shares of Stereotaxis common stock in the offering, including ... sold at a price to the public of $4.00 per ...
... 12 Leaders of the medical technology industry ... E. Washington Convention Center for the third annual ... mix of medical technology executives, innovators, policymakers, media, ... and 32 states, are expected to attend this ...
Cached Medicine Technology:Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 2Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 3Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 2Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 3
(Date:3/2/2015)... 2015 Representatives with BNatrl ( ... launched a multivitamin supplement that’s specifically designed for ... for BNatrl, said the multivitamin, which launched Jan. ... other world-class athletes. , "Being an avid marathon ... whole food multivitamin to improve my performance,” said ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... Final Cut Pro X plugin specialists have ... Film Studios. , “The TranStatic Volume 2 plugin gives users ... CEO of Pixel Film Studios. “TranStatic Volume 2 is a ... editors toolbox.” , With TranStatic Volume 2 users can transition ... scrambling effects from Pixel Film Studios. Users have total control ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
Breaking Medicine News(10 mins):Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... of brain tumor , , MONDAY, June 2 (HealthDay News) -- ... malignant brain tumor that was diagnosed last month. , The ... an especially lethal type of brain tumor, at Duke University ... Massachusetts Democrat,s office said he would be operated on by ...
... in 81 years the International Congress of Genetics takes place ... Nobel Prize winners get together with more than 2000 scientists ... genome analysis. The congress, which takes place for the 20th ... also being Berlin. Congress Chairman is Prof. Rudi Balling, Scientific ...
... PETERSBURG, Fla., June 2 The Advanced,Wound Management Division ... that its negative pressure wound therapy (NPWT) products will ... included in the,first phase of the competitive bidding program ... in the U.S. The program, which is,scheduled to take ...
... completed ... phase I studies, SAN ... of a worldwide exclusive agreement entered into in Feb,2008, GlaxoSmithKline (GSK) ... original agreement, GSK has rights to develop,manufacture and commercialize FLAP (5-Lipoxygenase ...
... Imagine being able to communicate,your practice,s message to ... practice growth and development. That is the focus of ... parent company of JG Pads, a pharmaceutical sales,support company ... United States since 1993. Because of its success, MarketHATCH ...
... Scientists at the University of Liverpool have found that ... antibiotics, suggesting that the infection is unlike the bacteria ... resistant to antibiotics and can sometimes go undetected in ... spread to humans. The team tested the strains found ...
Cached Medicine News:Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 2Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 3Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 4Health News:6 Nobel Prize Winners at International Congress of Genetics 2Health News:6 Nobel Prize Winners at International Congress of Genetics 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline 2Health News:Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 2Health News:Salmonella in garden birds responsive to antibiotics 2
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
... used to seal the arterial puncture site. Duett ... the arteriotomy and the tissue tract with a ... a balloon catheter and procoagulant - the Duett ... stop the bleeding. The Duett is unique in ...
Medicine Products: